Co-Authors
This is a "connection" page, showing publications co-authored by CHARLES F LEVENBACK and ROBERT COLEMAN.
Connection Strength
2.415
-
Current perspectives on lymphatic mapping in carcinomas of the uterine corpus and cervix. J Natl Compr Canc Netw. 2006 May; 4(5):471-8.
Score: 0.275
-
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. Int J Gynecol Cancer. 2020 11; 30(11):1768-1774.
Score: 0.187
-
A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). Gynecol Oncol Rep. 2019 Feb; 27:1-4.
Score: 0.164
-
Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol Oncol. 2015 Aug; 138(2):472-7.
Score: 0.129
-
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10; 33(8):930-6.
Score: 0.126
-
A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. Gynecol Oncol. 2014 Feb; 132(2):275-9.
Score: 0.116
-
Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Gynecol Oncol. 2013 Feb; 128(2):155-9.
Score: 0.108
-
Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol. 2013 Feb; 128(2):204-8.
Score: 0.108
-
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012 Nov 01; 30(31):3786-91.
Score: 0.105
-
Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol. 2009 Aug; 114(2):151-6.
Score: 0.086
-
Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol Oncol. 2008 Mar; 108(3):478-81.
Score: 0.077
-
Modified uterine manipulator and vaginal rings for total laparoscopic radical hysterectomy. Int J Gynecol Cancer. 2008 May-Jun; 18(3):571-5.
Score: 0.075
-
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.
Score: 0.070
-
Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol. 2006 Dec; 103(3):888-90.
Score: 0.069
-
Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Am J Obstet Gynecol. 2006 Apr; 194(4):1186-93; discussion 1193-5.
Score: 0.068
-
Electrothermal bipolar coagulation for pelvic exenterations. Gynecol Oncol. 2006 Sep; 102(3):534-6.
Score: 0.068
-
Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2006 Aug; 102(2):252-5.
Score: 0.068
-
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006 Apr; 101(1):126-31.
Score: 0.066
-
Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol. 2002 Feb 01; 20(3):688-93.
Score: 0.051
-
Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol. 2001 Nov; 83(2):276-81.
Score: 0.050
-
Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.
Score: 0.047
-
Abdominal sacral colpopexy in patients with gynecologic cancer and "Burch" not "Birch". Gynecol Oncol. 2000 Jun; 77(3):483-4.
Score: 0.046
-
Re: Terada et al.: Sentinel node dissection and ultrastaging in squamous cell cancer of the vulva. Gynecol Oncol 76:40-44, 2000. Gynecol Oncol. 2000 Jun; 77(3):484-5.
Score: 0.046
-
Laparoscopic sentinel node procedure in patients with cervical cancer. J Clin Oncol. 2002 May 15; 20(10):2602-3; author reply 2603.
Score: 0.026
-
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53.
Score: 0.026
-
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
Score: 0.026
-
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9.
Score: 0.023
-
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010 Nov 01; 116(21):4973-9.
Score: 0.023
-
Laparoscopic colostomy in gynecologic cancer. J Minim Invasive Gynecol. 2008 Nov-Dec; 15(6):723-8.
Score: 0.020
-
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008 Jul; 110(1):56-9.
Score: 0.020
-
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol. 2008 Jan; 108(1):68-71.
Score: 0.019
-
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007 May; 105(2):404-8.
Score: 0.018
-
Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol. 1995 May; 57(2):215-20.
Score: 0.008